IFP Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-20
| Closed | -$426 | – | 5138 |
|
|
2026
Q1 | $426 | Hold |
20
| – | – | ﹤0.01% | 4454 |
|
|
2025
Q4 | $431 | Hold |
20
| – | – | ﹤0.01% | 4322 |
|
|
2025
Q3 | $305 | Buy |
+20
| New | +$260 | ﹤0.01% | 4298 |
|
|
2025
Q2 | – | Hold |
0
| – | – | – | 3943 |
|
|
2025
Q1 | – | Hold |
0
| – | – | – | 3846 |
|
|
2024
Q4 | – | Hold |
0
| – | – | – | 3911 |
|
|
2019
Q1 | – | Sell |
-1,000
| Closed | -$2K | – | 2424 |
|
|
2018
Q4 | $2K | Hold |
1,000
| – | – | ﹤0.01% | 3122 |
|
|
2018
Q3 | $4K | Buy |
+1,000
| New | +$5.4K | ﹤0.01% | 3270 |
|
|
2017
Q4 | – | Sell |
-8,535
| Closed | -$90K | – | 3807 |
|
|
2017
Q3 | $90K | Hold |
8,535
| – | – | ﹤0.01% | 1616 |
|
|
2017
Q2 | $94K | Hold |
8,535
| – | – | ﹤0.01% | 1556 |
|
|
2017
Q1 | $83K | Hold |
8,535
| – | – | ﹤0.01% | 1614 |
|
|
2016
Q4 | $89K | Buy |
8,535
+50
| +0.6% | +$549 | ﹤0.01% | 1521 |
|
|
2016
Q3 | $105K | Hold |
8,485
| – | – | 0.01% | 1328 |
|
|
2016
Q2 | $91K | Buy |
+8,485
| New | +$90.5K | 0.01% | 1395 |
|
|
2016
Q1 | – | Sell |
-8,085
| Closed | -$99K | – | 2425 |
|
|
2015
Q4 | $99K | Buy |
+8,085
| New | +$126K | 0.01% | 1181 |
|
Other funds holding AVDL
IFP Advisors's AVDL Position: Q2 2026 in Review
IFP Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q2 2026, closing a stake of 20 shares — an estimated $426 sold.
IFP Advisors first reported a position in AVDL in Q4 2015 and held it in 12 quarters. The position peaked at $105K in Q3 2016. 1 fund tracked by Wall St. Rank holds AVDL as of Q2 2026.
- IFP Advisors reported no remaining Avadel Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- IFP Advisors sold 20 Avadel Pharmaceuticals shares in Q2 2026, an estimated $426.
- IFP Advisors first reported a position in Avadel Pharmaceuticals in Q4 2015 and held it in 12 quarters.
- IFP Advisors's Avadel Pharmaceuticals position peaked at $105K in Q3 2016.
- 1 fund tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.